CN110876624A - Analyte monitoring and automatic drug delivery system - Google Patents

Analyte monitoring and automatic drug delivery system Download PDF

Info

Publication number
CN110876624A
CN110876624A CN201811033862.9A CN201811033862A CN110876624A CN 110876624 A CN110876624 A CN 110876624A CN 201811033862 A CN201811033862 A CN 201811033862A CN 110876624 A CN110876624 A CN 110876624A
Authority
CN
China
Prior art keywords
blood sugar
injection
days
subject
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811033862.9A
Other languages
Chinese (zh)
Inventor
张艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201811033862.9A priority Critical patent/CN110876624A/en
Publication of CN110876624A publication Critical patent/CN110876624A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
    • A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

The invention provides an analyte monitoring and automatic drug delivery system, which comprises an injection detection device, a temporary storage device and a main control device, wherein the injection detection device is detachably connected with the temporary storage device or the main control device; the temporary storage device is detachably connected with the main regulation and control device; the injection detecting device comprises at least two detecting parts, at least two injection parts and a substrate, wherein each detecting part is used for detecting an analysis object in an analyte, and each injection part is used for injecting a medicine. The temporary storage device comprises a temporary data storage device and a temporary medicine storage device, the main control device comprises a second medicine storage part and an injection pump, and the temporary storage device is detachably connected with the main control device. The analyte monitoring and automatic drug delivery system provided by the invention is convenient to use, generates pain to patients, and has the advantages of low production cost and small volume.

Description

Analyte monitoring and automatic drug delivery system
Technical Field
The present invention relates to a system for monitoring an analyte (e.g. glucose or blood ketones) and corresponding automatic drug delivery. More particularly, the present invention relates to a system for monitoring an analyte in a body using an electrochemical sensor and automatically administering a drug according to the monitoring result.
Background
Diabetes is a disease which is relatively common in our lives. It is well known that diabetes is a group of metabolic diseases characterized by hyperglycemia, which results from the inability of the pancreas to produce sufficient amounts of insulin, resulting in a reduced ability of the body to metabolize glucose, and thus, hyperglycemia (i.e., excess glucose present in the plasma). However, the medical level is not well developed at present, and a method for radically treating diabetes is not found, and only the dosage of hypoglycemic drugs can be adjusted by detecting the blood sugar of a diabetic patient through a detection method, so that the symptoms of the patient can be relieved.
In recent years, the mainstream monitoring method of blood sugar is fingertip blood sugar test, namely, a finger is pricked by a needle, and blood is collected and then reflected by test paper to the blood sugar level in a human body. The fingertip blood sugar test is simple and convenient, and is also accepted and applied by a large number of diabetics. However, in most cases, the measurement of blood glucose by fingertips of diabetic patients can be performed only at discrete time points, and the measurement method cannot show the variation trend of the blood glucose level of the patients in a period of time. Therefore, even the most active frequent blood glucose testers cannot find the frequent hyperglycemia or hypoglycemia, and it is difficult to observe the specific condition of blood glucose fluctuation. Especially at night. In addition, this method also does not facilitate recording of blood glucose data for the patient. Furthermore, the consistency of monitoring due to blood glucose levels varies greatly between individuals.
Further, over the years, although many devices have been developed for continuous or automated monitoring of analytes, such as glucose, in the blood stream or interstitial fluid. Many of these devices use electrochemical sensors. However, most of these devices require direct implantation into the patient's blood vessels or into the subcutaneous tissue, not only are they difficult to reproduce on a large scale or to produce inexpensively, but they are generally large, bulky, and/or inflexible, and many cannot be effectively utilized outside of a controlled medical facility (e.g., a hospital or doctor's office), which greatly limits the patient's freedom of movement.
The existing insulin injection device generally uses a common needle to inject insulin, and the needle has obvious pain when puncturing the skin. Meanwhile, if a patient wears the existing insulin injection device for a long time and needs the needle to be left in the skin for a long time, it is necessary to take sterilization measures from time to time, or wound infection due to sweat or the like may occur. In addition, because the needle needs to penetrate into the dermis for insulin injection, the needle is generally long, and the skin is easy to scar after long-term wearing.
In addition, because the existing insulin injection devices use a common needle head to inject the insulin, the injection position is concentrated, subcutaneous induration is easy to generate at the injection position, and discomfort is brought to patients. Further, the concentration of the injection site tends to slow the absorption of insulin, resulting in poor therapeutic effect.
Disclosure of Invention
The invention aims to provide an analyte monitoring and automatic drug delivery system, which can solve the problems of inconvenient use, pain feeling to patients, higher production cost, larger volume and the like of the analyte monitoring and automatic drug delivery system in the prior art, and further solve the problems of inconvenient use, pain feeling to patients, slow drug absorption, poor treatment effect and the like of a drug injection device in the prior art.
In order to solve the problems, the invention provides an analyte monitoring and automatic drug delivery system, which comprises an analyte monitoring and automatic drug delivery system and is characterized by comprising a filling device, a temporary storage device and a main control device,
the injection detection device is detachably connected with the temporary storage device or the main regulation and control device;
the temporary storage device is detachably connected with the main regulation and control device;
the injection detecting device includes at least two detecting parts, at least two injection parts and a substrate, each detecting part is used for detecting an analysis object in an analyte, each injection part is used for injecting a medicine, each detecting part and each injection part are formed into a needle-shaped member with one end attached to one side surface of the substrate and a fluid channel formed inside, and the other end of each detecting part and each injection part is formed into a tip; the depth of each detection component and each injection component inserted into the interstitial tissue of a patient is between 0.3mm and 5 mm;
the temporary storage device comprises a temporary data storage device and a temporary medicine storage device;
the temporary data storage device is used for temporarily storing the detection results of all the detection components; sending the stored detection result to a main control device;
the temporary drug storage device comprises a first drug storage part and a piston type pushing piece;
the main control device comprises a second medicine storage part and an injection pump;
the substrate further comprises a medicine distribution passage, and the first medicine storage part or the second medicine storage part is communicated with each injection part through the medicine distribution passage;
furthermore, the injection checking device is detachably connected with the temporary storage device through a first connecting piece;
the injection detection device is detachably connected with the main regulation device through a second connecting piece;
the temporary storage device and the main control device are detachably connected through a third connecting piece.
Furthermore, the main control device also comprises a processor and a controller, wherein the processor analyzes and processes the detection results of the detection parts to obtain processing numerical values corresponding to the detection results of the detection parts; the processor is also used for comparing and calculating the processing value corresponding to each detection component to obtain an instant monitoring result; the processor is also used for calculating the total injection quantity of the medicine; the controller is used for controlling the injection device and the processor.
Further, there is provided according to another aspect of the present invention an analyte monitoring and automatic drug delivery system, wherein: the processor calculates the total injection amount of the medicine according to the weight, the waist-hip ratio, the triglyceride content in blood, the blood sugar monitoring value before meals and the blood sugar change trend in three days of a patient; and is
The processor calculates the total injected amount of the drug according to the following formula:
Figure BDA0001790394160000031
wherein:
L1: a total injection amount (u) of the medicine calculated by the calculation unit;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: and a is 0.6.
Further, there is provided according to another aspect of the present invention an analyte monitoring and automatic drug delivery system, wherein: the processor calculates the total injection amount of the medicine according to the weight, the waist-hip ratio, the triglyceride content in blood, the blood sugar before meal monitoring value, the blood sugar after meal monitoring value and the blood sugar change trend in three days of the patient; and is
The processor calculates the total injected amount of the drug according to the following formula:
Figure BDA0001790394160000041
wherein:
L2: a total injected amount (u) of the drug calculated by the processor;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: a is 0.6; and
b: mean blood glucose (mmol/L) after a single day of injection of the subject;
b: a trend of postprandial blood glucose change within three days of the injected subject, wherein:
when the postprandial blood glucose change for the injected subjects was overall within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes after three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 10% and within 20% compared with the blood glucose minimum value: a is 1.2;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 20% and within 30% compared with the blood glucose minimum value: a is 1.3;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 30% and within 40% compared with the blood glucose minimum value: a is 1.4;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 40% compared with the blood glucose minimum value: a is 1.5; and is
When the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 10% compared with the blood sugar maximum value: a is 0.9;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 40% compared with the blood sugar maximum value: a is 0.6; and is
Medicine injection amount L before breakfast21＝L2×0.6；
Medicine injection L before supper22＝L2×0.4。
Further, each detection part includes a working electrode and a reference electrode, the working electrode and the reference electrode being formed of different materials; the peripheral surface of each working electrode is also provided with an electron transfer layer;
the processor is used for analyzing and processing the electric signals between the working electrode and the reference electrode in each detection part, so as to obtain corresponding processing values corresponding to each detection part.
Further, the main control device further comprises: the processor may also accept user settings for the analyte monitoring and automatic drug delivery system. The input device and the processor are electrically connected with the controller.
Furthermore, the main control device also comprises a prompter, and the processor is also used for comparing the processing values corresponding to the detection results of the detection components one by one, and comparing the comparison values obtained after one-to-one comparison with preset threshold values respectively; if the obtained comparison value is larger than the threshold value, the prompter gives an alarm; the prompter is electrically connected with the controller.
Further, the main control device further comprises: the display is used for displaying the calculation result of the processor; the storage stores the calculation result of the processor; the display and the storage are respectively electrically connected with the controller.
Further, the master control device further comprises a transmitter for transmitting the calculation result of the processor and/or the calculation result stored in the storage.
The invention has the beneficial effects that:
the present invention provides an analyte monitoring and automatic drug delivery system comprising: the injection detection device is detachably connected with the temporary storage device or the main regulation and control device; the injection detection device comprises a detection part, injection parts and a substrate, wherein the detection parts are used for detecting an analysis object in an analyte, and the injection parts are used for injecting medicine; the temporary storage device comprises a temporary data storage device and a temporary medicine storage device; the temporary data storage device is used for temporarily storing the detection results of all the detection components; and transmitting the stored detection result to the main control device; the analyte monitoring and automatic drug delivery system provided by the invention is convenient to use, generates pain to patients, and has the advantages of low production cost and small volume.
In order to make the aforementioned and other objects of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
The invention will now be described with reference to the accompanying drawings.
FIG. 1a is a schematic perspective view of a primary control device, a temporary storage device, and a filling device of an analyte monitoring and automatic drug delivery system according to an embodiment of the present invention;
FIG. 1b is a schematic perspective view of a temporary storage device and a priming device of an analyte monitoring and automatic drug delivery system according to an embodiment of the present invention;
FIG. 1c is a schematic diagram of another perspective view of a temporary storage and a priming device of an analyte monitoring and automatic drug delivery system according to an embodiment of the present invention;
FIG. 1d is a schematic perspective view of a temporary storage device and a primary control device of an analyte monitoring and automatic drug delivery system provided in an embodiment of the present invention;
FIG. 2a is a schematic perspective view of an injection portion of an analyte monitoring and automatic drug delivery system according to an embodiment of the present invention;
FIG. 2b is a schematic diagram of another embodiment of an injection site of an analyte monitoring and automatic drug delivery system;
FIG. 2c is a schematic diagram of another embodiment of an injection site of an analyte monitoring and automatic drug delivery system;
FIG. 3 is a schematic perspective view of an analyte monitoring and temporary storage device of an automated drug delivery system according to an embodiment of the present invention;
FIG. 4 is a schematic perspective view of a primary control device of an analyte monitoring and automatic drug delivery system according to an embodiment of the present invention;
FIG. 5 is a schematic diagram of an electrical connection configuration of the components of an analyte monitoring and automatic drug delivery system provided by an embodiment of the present invention.
Reference numerals:
1. a filling device; 11. a detection section; 12. a substrate; 13. an injection component; 2. a temporary storage device; 21. a first drug storage component; 22. a piston-type pusher; 3. a main control device; 31. a processor; 32. a controller; 33: a prompter; 34. a display; 35. a reservoir; 36. a transmitter; 37: an input device; 38. a first drug storage component; 39. an injection pump; 311: a processing unit; 312: a comparison unit; 313: a calculation unit; 314: a setting unit; 40. a first connecting member; 41. a second connecting member; 42. a third connecting member; 50. a slide rail; 51. a slider; 52. a card slot; 53. a clamping block; 54. a first adhesive end; 55. and a second adhesive end.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be readily apparent to those skilled in the art from the disclosure of the present specification.
Referring to fig. 1-5, the present invention provides an analyte monitoring and automatic drug delivery system, which is characterized in that the system comprises a detection and injection device 1, a temporary storage device 2 and a main control device 3, wherein the detection and injection device 1 is detachably connected with the temporary storage device 2 or the main control device 3; in practical application, when the analyte monitoring and automatic drug delivery system needs to be applied, the injection device 1, the temporary storage device 2 and the main control device 3 can be detachably connected; after the use, can examine annotating device 1, temporary storage device 2 and main regulation and control device 3 through dismantling the separation, make it can store respectively, reduced analyte monitoring and automatic drug delivery system's storage space under the non-user state to effectively solved among the prior art analyte monitoring and the great problem of automatic drug delivery system volume.
Referring to fig. 2, the injection device 1 includes at least two detection parts 11, at least two injection parts 13, and a substrate 12, each detection part 11 for detecting an analysis object in an analyte, each injection part 13 for injecting a medicine, each detection part 11 and each injection part 13 formed as a needle-shaped member having one end attached to one side surface of the substrate 12 and having a fluid channel formed therein, and the other end of each detection part 11 and each injection part 13 formed as a tip; the substrate 12 is formed of a flexible material; the depth of each detection part 11 and each injection part 13 inserted into the interstitial tissue of the patient is between 0.3mm and 5 mm;
further, the analyte monitoring and automatic drug delivery system provided according to the present invention may be used to determine the concentration of an analyte (e.g., glucose or blood ketones in body fluids) in the human body. For example, continuous or periodic monitoring of analytes in the interstitial fluid of a patient may be used to indicate the glucose level in the patient's bloodstream. Further, in accordance with the analyte monitoring and automatic drug delivery system provided by the present invention, the sensing component 11 may be an implantable sensor, or other in vivo analyte sensors may be used, for insertion into a vein or other site in the body containing bodily fluids. Typically, analyte monitoring and automated drug delivery systems provided in accordance with the present invention may be configured to monitor the level of analyte in a patient over a period of time (which may range from several days to several weeks or more). Further, the detecting part 11 may further include a circuit reading part such as an ammeter to acquire a signal of each detecting part 11 to obtain a detection result.
Further, the injection part 13 comprises at least two injection parts 13, wherein each injection part 13 is used for injecting a medicament. More specifically, in the analyte monitoring and automatic drug delivery system provided according to the present invention, the injection component 13 may be an implantable syringe, or other in vivo syringes may be used for insertion into a vein or other site in the body containing bodily fluids. It will be appreciated that each of the sensing part 11 and the injection part 13 has a size much smaller than that of a general syringe needle, so that when the sensing part 11 provided in the present invention is used for analyte monitoring and the injection part 13 is used for drug injection, pain of a patient is greatly reduced, and since the skin penetration depth of the sensing part 11 and the injection part 13 is small, wound infection is not caused, and scars are not left due to long-term wearing.
Further, in the preferred embodiment of the present invention, the substrate 12 may be flexible to reduce pain and tissue damage to the patient when the sensing part 11 and the injection part 13 are implanted and/or worn. The flexible substrate 12 generally increases patient comfort and allows the patient greater range of motion. Suitable materials for the flexible substrate 12 include materials such as non-conductive plastics or polymers and other non-conductive, flexible, deformable materials. Examples of useful plastics or polymeric materials include thermoplastics such as polycarbonate, polyethylene terephthalate (PET), polyvinyl chloride (PVC), polyurethanes, polyethers, polyamides, polyimides, or copolymers of these thermoplastics, for example PETG (glycol modified polyethylene terephthalate).
Further, the substrate 12 in an analyte monitoring and automatic drug delivery system according to the present invention may also be rigid, depending on the actual use and design requirements. The use of a rigid substrate 12 provides structural support for the detection component 11 and the injection component 13 to resist bending or cracking. More specifically, examples of rigid materials that may be used as substrate 12 include poorly conductive ceramics, such as alumina and silica. Another advantage of using a rigid substrate 12 is that it facilitates the insertion of the detection part 11 and the injection part 13 without the need for additional insertion means.
Furthermore, it will be apparent to those skilled in the art that for many detection members 11 and injection members 13, both rigid and flexible substrates 12 may be suitably used, and their flexibility may be continuously varied, for example by varying the composition and/or thickness of the substrate 12, depending on the particular use and design requirements. These may be determined by one skilled in the art based on specific use and design requirements.
Further, each of the injection parts 13 is formed as a needle-shaped member having one end attached to one side surface of the substrate 12 and a fluid passage formed inside, and the other end of each injection part 13 is formed as a tip. When the injection members 13 are inserted into the skin of a patient, the medicine flows into the patient through the tip of each injection member 13. That is, in the analyte monitoring and automatic drug delivery system according to the preferred embodiment of the present invention, the detection component 11 and the injection component 13 are formed on the same side surface of the substrate 12 (i.e., the side surface facing the surface of the human body in the use state), for example, for convenience of manufacturing and control, as shown in the drawings of the attached specification, the detection component 11 is formed on one side surface of the substrate 12, and the injection component 13 is formed on the other side surface of the substrate 12. Referring to fig. 2b and 2c, the sensing part 11 is formed at the right of one side surface of the substrate 12, and the injection part 13 is formed at the left of one side surface of the substrate 12.
Further, in using the analyte monitoring and automatic drug delivery system according to the preferred embodiment of the present invention, the user inserts the sensing parts 11 and the injection parts 13 provided on the substrate 12 into predetermined positions on the surface of the human body, not only so that the working electrode and the reference electrode of each sensing part 11 are located in the analyte (e.g., glucose, oxygen, triglyceride or ketone body) of the analyte-containing liquid (e.g., body fluid, sample fluid or carrier fluid) to monitor the analyte, but also so that each injection part 13 is located in a vein or a site containing the body fluid to facilitate the injection of the drug into the human body. Still further, for example, the implantation of the detection component 11 and the injection component 13 may be performed in an intravenous system for directly testing the analyte level in blood and directly injecting a drug into the blood. Alternatively, the detection member 11 may be implanted in interstitial tissue for determining the analyte level in interstitial fluid, which may be correlated and/or converted to the analyte level in blood or other fluids. Meanwhile, the injection part 13 is implanted into the interstitial tissue for injecting the drug into the interstitial fluid. In this case, the position and depth of implantation of the detection part 11 and the injection part 13 may affect the specific shape, parts and structure of the detection part 11 and the injection part 13.
Further, according to the preferred embodiment of the present invention, the sensing part 11 and the injection part 13 provided on the substrate 12 are inserted into the interstitial tissue (between 0.3mm and 5 mm) of the patient. Preferably, it is inserted into the interstitial tissue, 0.5mm to 3mm, more preferably 0.5mm to 1.5 mm. Other embodiments of the invention may include a sensing component 11 and an injection component 13 that are inserted into other parts of the patient, such as a vein or organ. The depth of implantation varies depending on the target to be implanted. Further, an adhesive substance may be coated on the surface of the substrate 12 on which the sensing part 11 is disposed, so that the sensing part 11 and the injection part 13 are fixed in the patient's body by the adhesive substance on the surface of the substrate 12 after the sensing part 11 and the injection part 13 are inserted into the patient's epidermis, thereby facilitating the patient to monitor the analyte level for a period of time and to inject the drug into the patient without re-inserting the sensing part 11 and the injection part 13 every measurement.
Further, the insertion angle is measured from the skin plane (i.e. the insertion angle should be 90 ° perpendicular to the skin insertion sensor). The insertion angle is typically in the range of 10 ° to 90 °, typically 15 ° to 60 °, more often 30 ° to 45 °. With such a configuration, a patient may experience a significantly reduced pain when using the analyte monitoring and automatic drug delivery system provided by the present invention. Still further, optionally, the substrate 12, the detection component 11 and the injection component 13 in the analyte monitoring and automatic drug delivery system provided according to the present invention are formed in a shape that is comfortable for the patient, which may allow hiding under, for example, the patient's clothing. The thigh, leg, upper arm, shoulder or abdomen are relatively convenient parts of the patient's body for placing the detecting member 11 to keep hidden. However, the detection part 11 and the injection part 13 may also be placed at other parts of the patient's body.
Referring to fig. 1a, fig. 1b and fig. 1c, when the blood glucose analysis needs to be performed outdoors, in order to avoid the main control device 3 from being too large in size and not portable, the temporary storage device 2 may be used to temporarily store the detection results of the detection components 11; the stored detection result is transmitted to the main control device 3 after the indoor environment is returned; the temporary storage means 2 comprises temporary data storage means 23 and temporary drug storage means 22; the temporary data storage device is used for temporarily storing the detection results of the detection parts 11; and transmitting the stored detection result to the main control device 3; after the operation of collecting the detection analyte is completed, each detection component 11 performs detection analysis, and then transmits the detection result of the detection analyte to the temporary data storage device for short-time storage, and at the same time, the temporary data storage device transmits the obtained detection result of the detection analyte to the main control device 3, so as to further analyze and process the detection result of the detection analyte through the main control device 3 to obtain a processing value corresponding to the detection analysis result, and then compares and calculates the processing value with the processing value corresponding to each detection component 11 to obtain a calculation result. It should be understood that the temporary data storage device includes a memory chip information reading component and an information storage component, and an electronic component such as a memory chip having information identification, reading and storage functions, and the model and structure of the specific electronic component of this type may be selected according to actual needs, which is not limited in this embodiment. Further, the temporary drug storage device comprises a first drug storage part 21 and a piston-type pusher 22. The temporary medicament storage means 21 is adapted to perform a temporary holding operation for the medicament to facilitate the injection component 13 taking the injected medicament to the temporary medicament storage means 2 for the injection operation. More specifically, the temporary medicine storage device includes a first medicine storage component 21 for storing the injected medicine, and the specific structure may be a medicine storage box or a medicine storage box, or a storage component with another structure may be used for storing the medicine, and the specific structure may be selected according to actual needs, which is not specifically limited in this embodiment. More specifically, the temporary drug storage device 2 further comprises a piston-type pusher 22, and the piston-type pusher 22 may specifically comprise a push rod and a piston head, for pushing up a small amount of the remaining injected drug in the first drug storage section 21 through the piston-type pusher 22, so as to facilitate the drug collection of the injection section 13.
Referring to fig. 4, further, the main control device 3 includes a second medicine storage part 38 and a syringe pump 39; the second medicine storage part 38 is used for storing medicine for injection, on one hand, the second medicine storage part can directly provide the medicine for injection to the injection part 13, on the other hand, a small amount of temporarily and conveniently available medicine for injection can also be provided to the first medicine storage part 21 in the temporary medicine storage device, the specific structure of the second medicine storage part can be a medicine storage box or a medicine storage box, or a storage part with other structure can be used for storing medicine, the specific structure can be selected according to actual needs, and the embodiment is not limited to this. The syringe pump is used for pumping out the residual medicine in the second medicine storage part 38 through the syringe pump 39 and delivering the residual medicine to the injection part 13 or the first medicine storage part 21, so that the medicine can be taken out by the injection part 13 or the first medicine storage part 21 conveniently.
Referring to fig. 2, further, the substrate 12 further includes a medicine distribution passage (not shown), and the first medicine storage part 21 or the second medicine storage part is communicated with each injection part 13 through the medicine distribution passage; the substrate in the injection device 1 is provided with a medicine distribution passage for communicating the first medicine storage part 21, the second medicine storage part and each injection part 13, so that the first medicine storage part 21 can take medicine from the second medicine storage part through the medicine distribution passage and can also convey the medicine to the first medicine storage part 21 through the medicine distribution passage; it is also possible that the second or first drug storage part 21 delivers the drug to the injection part 13 through the drug dispensing passage, or the injection part 13 takes the drug from the second or first drug storage part 21 through the drug dispensing passage.
Referring to fig. 1a, fig. 1b and fig. 1c, further, the injection device 1 is detachably connected to the temporary storage device 2 through a first connecting member 40; the injection detecting device 1 is detachably connected with the main control device 3 through a second connecting piece 41; further, the temporary storage device 2 and the main control device 3 are detachably connected by a third connecting member 42.
Referring to fig. 1a, further, the first connecting element 40 of the present embodiment may be a slide rail 50 and a slide block 51 matched with the slide rail 50; referring to fig. 1b, the first connecting member 40 may also be a card slot 52 and a card block 53 matching with the card slot 52, referring to fig. 1c, the first connecting member 40 in this embodiment may also be a first adhesive end 54 and a second adhesive end 55 matching with the first adhesive end 54.
Similarly, in fig. 1b, the second connecting member 41 may be a slide rail 50, and a slide block 51 matched with the slide rail 50; referring to fig. b, the second connecting member 41 may also be a card slot 52 and a card block 53 matching with the card slot 52, referring to fig. 1c, the second connecting member 41 of this embodiment may also be a first adhesive end 54 and a second adhesive end 55 matching with the first adhesive end 54.
Similarly, in fig. 1c, the third connecting member 42 may be a slide rail 50, and a slide block 51 matched with the slide rail 50; referring to fig. 1b, the third connecting member 42 may also be a card slot 52 and a card block 53 matching with the card slot 52, and referring to fig. 1c, the third connecting member 42 in this embodiment may also be a first adhesive end 54 and a second adhesive end 55 matching with the first adhesive end 54.
Referring to fig. 5, further, the main control device 3 further includes a processor 31 and a controller 32, the processor 31 analyzes and processes the detection result of each detection component 11 to obtain a processing value corresponding to the detection result of each detection component 11; the processor 31 is also used for carrying out comparison calculation on the processing value corresponding to each detection component 11 to obtain an instant monitoring result; the processor 31 is also used for calculating the total injection amount of the medicine; the controller 32 is used to control the filling device 1 and the processor 31. A controller 32, specifically an 8051 single chip microcomputer; the processor 31 is specifically an REALLIGHT model TT-APC-TP3001-3003 processor 31, and may be of other models, which is not limited in this embodiment.
Further, there is provided according to another aspect of the present invention an analyte monitoring and automatic drug delivery system, wherein: the processor 31 calculates the total amount of the drug to be injected based on the patient's weight, waist-to-hip ratio, triglyceride level in blood, blood glucose monitor value, and recent trend of blood glucose change.
More particularly, there is provided in accordance with a preferred embodiment of the present invention an analyte monitoring and automatic drug delivery system, wherein: the processor 31 calculates the total injection amount of the drug based on the weight of the patient, the waist-to-hip ratio, the triglyceride content in blood, the blood glucose monitoring mean value before a single day meal, and the trend of blood glucose change over three days. And:
the calculation unit 3 calculates the total injection amount of the medicine according to the following formula:
Figure BDA0001790394160000131
wherein:
L1: the total amount of medication injected (u) by the processor 31 before a single daily meal for the patient;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: and a is 0.6.
More specifically, the inventor of the present invention performed a verification calculation of the insulin injection amount of 20 typical patients by a large number of multiple sampling, and the specific data table is shown in the following table 1:
TABLE 1
Figure BDA0001790394160000151
According to the table, the calculation method provided by the invention can accurately calculate the insulin injection amount before meal of the patient according to different body conditions of each patient, so that personalized treatment is performed. More specifically, according to the analyte monitoring and automatic drug delivery system provided by the invention, the total amount L1 of insulin injected before a single-day meal is calculated by the processor 31 according to the weight, waist-hip ratio, triglyceride content in blood, blood glucose monitoring mean value before the single-day meal and change trend of blood glucose before the three-day meal of a patient, and the injection is carried out before the meal by the injection component 13, so that the targeted and personalized treatment is carried out on each patient.
Still further, in accordance with another preferred embodiment of the present invention, there is provided an analyte monitoring and automatic drug delivery system, comprising: the processor 31 calculates the total injection amount of the medicine according to the weight, waist-hip ratio, triglyceride content in blood, blood glucose monitoring mean value before single-day meal, blood glucose monitoring mean value after single-day meal and blood glucose change trend in three days of the patient; and is
The processor 31 calculates the total injection amount of the drug according to the following formula:
Figure BDA0001790394160000152
wherein:
L2: the total amount of drug injected per day (u) by the processor 31;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: a is 0.6; and
b: mean blood glucose (mmol/L) after a single day of injection of the subject;
b: a trend of postprandial blood glucose change within three days of the injected subject, wherein:
when the postprandial blood glucose change for the injected subjects was overall within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes after three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 10% and within 20% compared with the blood glucose minimum value: a is 1.2;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 20% and within 30% compared with the blood glucose minimum value: a is 1.3;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 30% and within 40% compared with the blood glucose minimum value: a is 1.4;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 40% compared with the blood glucose minimum value: a is 1.5; and is
When the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 10% compared with the blood sugar maximum value: a is 0.9;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 40% compared with the blood sugar maximum value: a is 0.6; and is
Injection amount L of medicine before single-day meal21＝L2X is 0.6; drug injection L after a single meal22＝L2×0.4。
More specifically, the inventors of the present invention performed a verification calculation of the insulin injection amounts of 20 typical patients listed in the above table 1, and the specific data table is shown in the following table 2:
TABLE 2
Figure BDA0001790394160000181
According to the table, the method for calculating the total insulin injection amount can accurately calculate the total drug (insulin) injection amount per day of the patient according to different physical conditions of each patient. Further, based on the calculated total amount of insulin injected per day of the patient, the amount of insulin injected before the meal of a single day L21 and the amount of insulin injected after the meal of a single day L22 are further calculated. More specifically, according to the method for calculating the total insulin injection amount provided by the invention, aiming at a patient needing to inject insulin twice a day, the medicine injection amount L21 before breakfast is L2 x 0.6; the injection amount of the medicine before breakfast is L22-L2 x 0.4.
More specifically, according to the analyte monitoring and automatic drug delivery system provided by the invention, the total amount of insulin injected per day L2 of each patient is accurately calculated by the processor 31 according to the weight, waist-hip ratio, triglyceride content in blood, blood glucose monitoring mean value before a single day meal, blood glucose monitoring mean value after a single day meal and blood glucose variation trend in three days, so as to obtain the pre-breakfast-drug injection amount L21 and the pre-breakfast-drug injection amount L22 of each patient, and further, the injection part 13 is used for accurately injecting the pre-breakfast drug and the pre-supper drug respectively, thereby performing targeted and personalized treatment on each patient.
Further, the processor 31 performs analysis processing on the detection result of each of the detection sections 11 to obtain a processing value corresponding to the detection result of each of the detection sections 11. Further, it is common for those skilled in the art that the detection result (signal) from each detection member 11 has at least one characteristic, for example, a change in current, voltage, or frequency as the concentration of the analyte changes. For example, if the detection component 11 operates using an ammeter, the signal current varies with the analyte concentration. In the present invention, the processor 31 may rectify and read the detection result of each detection part 11 to obtain a processed value in accordance with the change in the analyte concentration. Furthermore, the processor 31 according to the invention may also comprise circuitry for converting the information part carried by the detection result from one characteristic to another characteristic. For example, if the detection component 11 operates using an ammeter, the signal current varies with analyte concentration, in which case the processor 31 may be a current-to-voltage or current-to-frequency converter. The purpose of such conversion may be to provide a signal that is more easily transmitted, more easily read by digital circuitry, and/or less susceptible to noise, for example.
Further, the processor 31 further includes a calculation unit 313 and a comparison unit 312, and the calculation unit 313 performs comparison calculation on the processing value corresponding to each detection part 11 to obtain a calculation result. More specifically, since the detecting unit 11 includes at least two detecting units 11, the processor 31 analyzes and processes the detection result of each detecting unit 11 to obtain at least two corresponding processing values. Further, the comparison unit 312 according to the present invention performs a comparison calculation on at least two processed values, for example, performs an averaging calculation on at least two processed values, thereby obtaining an accurate calculation result. Further, the calculation unit 313 in the analyte monitoring and automatic drug delivery system according to the present invention can be further used to calculate the total injection amount of the drug, for example, the total injection amount of the drug required to be injected is calculated according to the calculation result calculated by the calculation unit 313, and the personal information provided by the user. Compared with the existing insulin injection device, the injection part 13 can inject the insulin in an accurate numerical value according to the characteristics of the patient, so that the discomfort of the patient caused by insufficient dosage or excessive dosage is avoided. Furthermore, because the injection part 13 comprises at least two injection parts 13, the injection of the medicine can be simultaneously carried out through the at least two injection parts 13, the injection area of the medicine can be effectively increased, the skin induration can be obviously improved, the medicine absorption effect can be effectively enhanced, and the treatment effect can be improved. Further, according to the preferred embodiment of the present invention, the injection part 13 includes a plurality of injection parts 13 arranged in an array form, thereby being most effective in increasing the injection area of the medicine, improving the skin induration, and enhancing the medicine absorption effect. Further, the injection member 13 according to the present invention may be made of dimethyl siloxane (PDMS) or other similar materials, and the surface thereof may be coated with various corrosion prevention layers to function as a seal.
Further, according to the analyte monitoring and automatic drug delivery system provided by the preferred embodiment of the present invention, the detecting component 11 and the processor 31 can monitor the physical condition (e.g., glucose content, ketone body content, oxygen content, etc.) of the user according to actual needs, and the calculating unit 313 calculates the corresponding calculation result (e.g., blood glucose average per day, blood glucose trend within three days, etc.) representing the physical condition; further, the calculation unit 313 calculates the total amount of insulin injections before the patient's meal and/or the total amount of insulin injections per day by combining the calculation result indicating the physical condition with other personal information (for example, the weight, the waist-hip ratio, the content of triglyceride in blood, etc.) of the patient, and further controls the injection unit 13 through the controller 32 to perform precise and quantitative insulin injections, thereby preventing the patient from being affected by discomfort due to insufficient or excessive dosage. In addition, according to the analyte monitoring and automatic drug delivery system provided by the invention, an accurate monitoring value related to the physical condition of the patient can be obtained through the simple structure of the detection part 11, and the injection area of the drug can be effectively increased, the skin induration can be obviously improved, the drug absorption effect can be effectively enhanced, and the treatment effect can be improved through the simple structure of the injection part 13
Further, the analyte monitoring and automatic drug delivery system further comprises a controller 32, wherein the controller 32 controls the detection part 11, the processor 31 and the injection part 13. More specifically, the controller 32 can control the detection part 11 according to the setting of the user and/or control the injection part 13 according to the calculation result of the calculation unit 313.
As described above, the analyte monitoring and automatic drug delivery system according to the present invention can be used to monitor the level of an analyte (e.g., glucose, oxygen, triglyceride or ketone) in a patient over a period of time, and further, at least two injection parts 13 of the injection parts 13 can be controlled by the controller 32 so that the injection parts 13 perform drug injection simultaneously, thereby effectively increasing the injection area of the drug, significantly improving the skin induration, and effectively enhancing the drug absorption effect and improving the treatment effect. Therefore, the controller 32 of the analyte monitoring and automatic drug delivery system according to the present invention may include control circuits such as a switching circuit, a clock circuit, etc. to control the detection part 11, the processor 31, the calculation unit 313, and the injection part 13, respectively, to enable monitoring of the analyte level of the patient at a predetermined timing (e.g., every two hours or more) using the detection part 11, and to perform analysis processing and calculation of the detection result using the processor 31 and the calculation unit 313 every time the detection part 11 completes the detection, to obtain a calculation result capable of accurately reflecting the analyte level of the patient, and to control the injection part 13 to perform accurate injection according to the calculation result of the calculation unit 313.
Further, each detection part 11 includes a working electrode and a reference electrode, the working electrode and the reference electrode being formed of different materials; the peripheral surface of each working electrode is also provided with an electron transfer layer; the processor 31 is configured to analyze and process the electrical signal between the working electrode and the reference electrode in each detection unit 11, so as to obtain a corresponding processing value corresponding to each detection unit 11. Each of the detecting members 11 is an electrochemical sensor, and includes a working electrode and a reference electrode. More specifically, in the present invention, an "electrochemical sensor" is a device configured to detect the presence and/or measure the level of an analyte in a sample by means of electrochemical oxidation and reduction reactions on the sensor. Further, the electrochemical sensor includes a working electrode and a reference electrode in the form of a "paired electrode" wherein the current through the working electrode is equal in magnitude but opposite in sign to the current through the reference electrode. Further, with such a configuration of the working electrode and the reference electrode, the analyte may undergo electro-oxidation or electro-reduction reactions of the analyte directly on the working electrode or via one or more electron transfer agents, and convert these reactions into an electrical signal that is related to the amount, concentration, or level of the analyte in the sample.
Further, according to the analyte monitoring and automatic drug delivery system provided by the present invention, the processor 31 analyzes and processes the electrical signal between the working electrode and the reference electrode in each detection component 11, so as to obtain a corresponding analysis result corresponding to each detection component 11. For example, when a potential is applied between the working electrode and the reference electrode, a current will flow. The current is the result of the electro-oxidation or electro-reduction reaction, and the processor 31 may directly read the magnitude of the current, so as to reflect the amount, concentration or level of the analyte as a processed value corresponding to the detection result of each detection member 11. Alternatively, the processor 31 may be a current-to-voltage or current-to-frequency converter, so as to convert the current obtained by the detection means 11 into a signal more easily transmitted by the voltage or frequency lamp, more easily readable by digital circuits, and/or less affected by noise.
Preferably, an analyte monitoring and automatic drug delivery system is provided according to a preferred embodiment of the present invention, wherein: the outer peripheral surface of each working electrode is also provided with an electron transfer layer. More specifically, in the present invention, the peripheral surface of each working electrode is provided with a working surface, which is a portion of the peripheral surface of the working electrode, on which an electron transfer agent is or may be coated, and which is configured to be exposed to an analyte-containing liquid. Further, in the present invention, an "electron transfer agent" is a compound that can carry electrons between an analyte and a working electrode directly or in cooperation with other electron transfer agents, wherein one example of the electron transfer agent is a redox mediator.
In particular, some analytes (e.g., oxygen) may be directly electro-oxidized or electro-reduced at the working electrode. Other analytes, such as glucose and lactose, require the presence of at least one electron transfer agent and/or at least one catalyst to facilitate the electro-oxidation or electro-reduction of the analyte. For analytes (e.g., oxygen) that can be directly electro-oxidized or electro-reduced at the working electrode, a catalyst can also be used. For those analytes that require an electron transfer agent and/or catalyst, each working electrode has an electron transfer agent and/or catalyst formed on or near the working surface of the working electrode. Typically, the working surface is formed on or near only a small portion of the working electrode, often near the tip of the working electrode, and is placed in optimal position to contact the analyte-containing fluid (e.g., a body fluid, a sample fluid, or a carrier fluid). More specifically, the electron transfer agent and/or catalyst may be formed as a solid composition located at the working surface. These components are preferably non-leachable from the working electrode, and more preferably are immobilized on the working electrode. For example, the components may be immobilized on a work surface. Alternatively, the electron transfer agent and/or catalyst may be immobilized within the working surface or between one or more membranes or films deposited onto the working surface, or these components may be immobilized in a polymer or sol-gel matrix. More specifically, the working surface of the working electrode may comprise a catalyst (such as glucose oxidase, lactate oxidase, or laccase) for catalyzing the reaction of the analyte and producing a reactant at the working electrode and/or an electron transfer agent (e.g., an electron transfer agent that facilitates the electro-oxidation of glucose, lactose, or oxygen, respectively) for transferring electrons either indirectly or directly (or both) between the analyte and the working electrode.
Further, according to an analyte monitoring and automatic drug delivery system provided by another aspect of the present invention, the working electrode and the reference electrode in each detection part 11 are formed of different materials. More specifically, in the preferred embodiment of the present invention, the working electrode and the reference electrode in each detecting member 11 are formed of two different types of conductive materials (e.g., carbon and silver/silver chloride) with a structure that enables more precise electro-oxidation or electro-reduction of the analyte, thereby obtaining precise results. Further, in the preferred embodiment of the present invention, one type of conductive material is applied to one side of the substrate 12, thereby reducing steps in the manufacturing process and/or easily overcoming alignment limitations during the process. For example, if the working electrode of each detection member 11 is formed using a carbon-based conductive material, and all the working electrodes are located on one side of the substrate 12; further, the reference electrode of each detecting member 11 is formed using a silver/silver chloride conductive material, and all the reference electrodes are located on the other side of the substrate 12. Therefore, for convenience of manufacture, the working electrodes and the reference electrodes may be formed on opposite sides of the substrate 12 in an array arrangement, respectively.
Further, the substrate 12 of the analyte monitoring and automatic drug delivery system provided according to the present invention is further provided with an electrical connector (not shown) connected to an external power source to supply power to the working electrode and the reference electrode in the sensing part 11 for performing an electro-oxidation or electro-reduction reaction on the analyte using the working electrode and the reference electrode.
Referring to fig. 5, further, the main control device 3 further includes: an input device 37 through which a user may input personal information into the drug auto-injection system, and a processor 31 may also accept user settings for the analyte monitoring and auto-administration system. An input device 37, through which a user may input personal information into the analyte monitoring and automatic drug delivery system via input device 37. More specifically, the user may input personal information such as the waist-hip ratio, the body weight, the triglyceride content in blood, the blood glucose monitoring value, etc. of the user into the analyte monitoring and automatic administration system through the input device 37, and the calculation unit 313 performs calculation according to the personal information input by the user and the insulin injection total amount calculation method provided by the present invention, so as to obtain the insulin injection total amount corresponding to the personal information, and further perform injection through the injection part 13. Alternatively, the user inputs his or her own personal information (e.g., waist-hip ratio, body weight, triglyceride content in blood) through the input device 37, and calculates the corresponding calculation result (e.g., blood glucose average per day, blood glucose trend within three days, etc.) representing the physical condition by combining with the calculation unit 313, and the calculation unit 313 calculates according to the total insulin injection amount calculation method provided by the present invention, so as to obtain the total insulin injection amount corresponding to the personal information, and then performs injection through the injection part 13. It should be understood that the input device 37, specifically, the I/O interface of the 51 single chip microcomputer, may also have other circuit structures, and this embodiment does not specifically limit this.
Referring to fig. 5, the main control device 3 further includes a setting unit 314, the setting unit 314 is used to set the usage conditions (e.g., the time period, time interval, etc. for monitoring the analyte) of the analyte monitoring and automatic drug delivery system, or the setting unit 314 is used by the user to set the usage status (e.g., meal time, power on/off time, etc. of the patient) of the analyte monitoring and automatic drug delivery system, and the setting unit 314 is used by the user to set the display mode, etc. of the analyte monitoring and automatic drug delivery system, so that the user can use the analyte monitoring and automatic drug delivery system according to his actual needs. Further, according to the analyte monitoring and automatic drug delivery system provided by the present invention, the input device 37 and the processor 31 are electrically connected to the controller 32, and the connection manner may be a circuit or a wire connection, which is not limited in this embodiment.
Referring to fig. 5, further, the main control device 3 further includes a prompter 33, and the processor 31 is further configured to compare the processing values corresponding to the detection results of the detection components 11 one by one, and compare the comparison values obtained after one-to-one comparison with preset threshold values; if the obtained comparison value is greater than the threshold value, the prompter 33 gives an alarm; the prompter 33 is electrically connected to the controller 32. Still further, the analyte monitoring and automatic drug delivery system provided according to the present invention further comprises a comparison unit 312; a comparison unit 312, wherein the comparison unit 312 compares the processing values obtained by the processor 31 corresponding to the detection result of each detection part 11 one by one, and compares the comparison value obtained after one-by-one comparison with a preset monitoring threshold value to obtain a monitoring comparison value. More specifically, as described above, in the analyte monitoring and automatic drug delivery system provided according to the preferred embodiment of the present invention, the processor 31 performs an analysis process on the detection result of each detection part 11, thereby obtaining a process value corresponding to the detection result of each detection part 11. That is, for at least two detection components 11, the processor 31 will obtain at least two processed values correspondingly. Further, the comparison unit 312 of the analyte monitoring and automatic drug delivery system provided by the present invention compares the at least two processing values obtained by the processor 31 one by one, so as to obtain at least one monitoring comparison value, which may be a difference or a ratio of the two processing values after comparison. Further, the comparing unit 312 compares at least one of the monitoring comparison values with a predetermined monitoring threshold, which may be a specific threshold preset in the comparing unit 312 or the controller 32 by the manufacturer, or a threshold set by the user through the setting unit 314 according to specific use requirements, and can be determined according to actual design and use requirements. Still further, the analyte monitoring and automatic drug delivery system provided according to the present invention further comprises an alarm 33, wherein the alarm 33 sends an alarm signal if at least one of the monitoring comparison values is compared with a predetermined monitoring threshold value by the comparing unit 312, wherein at least one of the monitoring comparison values is greater than the predetermined monitoring threshold value. More specifically, the prompter 33 may prompt with sound and/or light, and the prompter 33 may be a sound emitting part or a light emitting part, or a combination of both. With this configuration, the operational behavior of the analyte monitoring and automatic drug delivery system, and in particular the sensing component 11, can be readily achieved. More specifically, if one of the detecting components 11 is abnormal, the detecting result of the detecting component 11 is abnormal compared with the detecting results of other detecting components 11 around, and further the abnormal detecting result of the abnormal detecting component 11 is processed by the processor 31, and then an abnormal processing value inevitably occurs, and further the monitoring comparison value obtained by comparing the comparing unit 312 with the corresponding processing values of the other detecting components 11 is greater than the preset monitoring threshold value. In this case, the prompter 33 gives a prompt to notify the user that an operation abnormality occurs in one of the detecting members 11, thereby stopping monitoring and replacing the detecting member 11 or the detecting member 11 in time. It should be understood that the prompting device 33, specifically, the buzzer alarm system connected to the 51 single chip microcomputer, may also have other structures, and this embodiment is not particularly limited to this.
Further, in the analyte monitoring and automatic drug delivery system according to the preferred embodiment of the present invention, the comparing unit 312 can further compare the insulin injection amount (i.e., L or L as above) calculated by the calculating unit 313 with a preset drug threshold, and when the insulin injection amount (i.e., insulin injection amount) calculated by the calculating unit 313 is less than the preset drug threshold, a prompt is given to the user through the prompter 33. More specifically, for example, according to the preferred embodiment of the present invention, a preset medication threshold value may also be stored in the controller 32 or the comparing unit 312, and the medication threshold value may be u if the insulin injection amount calculated by the calculating unit 313 is smaller than the preset medication threshold value (i.e., L calculated by the calculating unit is smaller than u), the prompter 33 gives a prompt to the user to prompt the user that the user may choose not to inject insulin in this case, and perform the in vivo blood sugar control by taking a medicine orally or by controlling the diet, for example. More specifically, the prompter 33 may include a component that prompts the user by a light or sound, for example, a sound component or a light component.
Referring to fig. 5, the prompters 33 are respectively electrically connected to the controller 32, so that the controller 32 controls the prompters 33, and various feedbacks of the comparison prompters 33 can be fed back to other units through the controller 32.
Further, it will be apparent to those skilled in the art that the prompter 33 may emit different prompting signals under different circumstances. For example, when the monitoring comparison value is greater than the monitoring threshold value, the prompter 33 gives a prompt to the user by emitting light; when the medication comparison value is smaller than the medication threshold value, the prompter 33 gives a prompt to the user by sounding. Still alternatively, the prompter 33 may emit different color prompting lights (e.g., when the monitoring comparison value is greater than the monitoring threshold, the prompter 33 prompts the user by emitting red light; and when the medication comparison value is less than the medication threshold, the prompter 33 prompts the user by emitting other color lights (e.g., yellow or green light)) or different effect prompting sounds under different conditions, thereby facilitating the user to distinguish between the different conditions.
Referring to fig. 5, further, the main control device 3 further includes: a display 34, the display 34 is used for displaying the calculation result of the processor 31; and a storage 35, the storage 35 stores the calculation result of the processor 31; the display 34 and the storage 35 are electrically connected to the controller 32, respectively. Specifically, the display 34 is used for displaying the calculation result of the calculation unit 313. More specifically, as described above, in the analyte monitoring and automatic drug delivery system according to the preferred embodiment of the present invention, the calculation unit 313 performs the comparison calculation of the processing value corresponding to each sensing part 11, thereby obtaining an accurate calculation result, which is a value reflecting the analyte level of the patient. Further, the calculation result of the calculation unit 313 is displayed through the display 34, so that the patient can visually and instantly see the analyte level thereof through the display 34, thereby knowing the physical status. Further, the calculation unit 313 also performs calculation based on the personal information of the patient to obtain the insulin injection amount for the individual patient. Further, the display 34 displays the calculation result of the calculation unit 313, so that the patient can visually and instantly see the calculation result of the calculation unit 313 through the display 34, thereby knowing the total amount of the medicine to be injected into the body and knowing the disease treatment state. In addition, the display 34 can display personal information such as body weight, triglyceride level in blood, blood glucose monitoring value, etc. inputted by the patient through the input device 37, thereby knowing the physical condition thereof. It should be understood that the storage 35, specifically, the 00H-07H or 80H-FFH unit in the data storage 35 of the single chip microcomputer; the display 34 is, specifically, model QK84DPM2.3J of the remote technologies company, and may be other models, which is not limited in this embodiment.
Referring to fig. 5, further, the analyte monitoring and automatic drug delivery system provided by the present invention further includes a storage 35, wherein the storage 35 stores the calculation result of the calculation unit 313. More specifically, the storage 35 may be configured to store a plurality of calculation results of the calculation unit 313 for a time period (for example, hours or longer), so as to facilitate the user to extract and analyze the calculation results for the time period from the storage 35, and further obtain the usage status of the drug and the state change of the body of the user during the time period, and further make various adjustments.
Further, according to the analyte monitoring and automatic drug delivery system provided by the present invention, the display 34 and the reservoir 35 are electrically connected to the controller 32, respectively, so that the display 34 and the reservoir 35 are controlled by the controller 32, and various feedback of the display 34 and the reservoir 35 can be fed back to other units by the controller 32.
Preferably, according to the analyte monitoring and automatic drug delivery system provided by the present invention: the processor 31, the input device 37, the setting unit 314, the reminder 33, the display 34, the memory 35, the transmitter 36 and the controller 32 are enclosed in the same housing. Further, in preferred embodiments of the invention, the housing is at least waterproof to prevent liquid from flowing into contact with components in the housing. In some embodiments, the housing is formed as a sealed, waterproof or water-resistant seal so that liquid cannot flow into the interior of the housing, which is useful when a user is performing activities such as showering, bathing or swimming. In addition, the shape of the housing can be arbitrarily selected according to actual design and use requirements, for example, the housing can be formed to have a circular, oval or other various shapes in cross section as long as the housing is adapted to the body of the user for use.
Referring to fig. 1, the main control device 3 further includes a transmitter 36, and the transmitter 36 is configured to transmit the calculation result of the processor 31 and/or the calculation result stored in the storage 35. Still further, according to another aspect of the present invention, there is provided an analyte monitoring and automatic drug delivery system, further comprising: a transmitter 36, the transmitter 36 being configured to transmit the calculation result of the calculation unit 313 and/or the calculation result stored in the storage 35. More specifically, according to the preferred embodiment of the present invention, the transmitter 36 can send the calculation results of the calculation unit 313 and/or the calculation results stored in the storage 35 to the outside in a wired (e.g., data transmission line) or wireless (e.g., wireless network, bluetooth transmission, etc.) manner. So that the user can obtain the calculation results of the calculation unit 313 and/or the calculation results stored in the storage 35 by means of e.g. a wired/wireless handheld device. Further, if the user's mobile phone has application software (mobile phone App) adapted to the analyte monitoring and automatic drug delivery system provided by the present invention installed therein, the calculation result of the calculation unit 313 and/or the calculation result stored in the storage 35 can be easily obtained on the mobile phone by pairing with the transmitter 36 (e.g., bluetooth pairing, wireless network pairing, etc.), so as to grasp the physical condition of the patient at any time. In addition, for a medical institution, a plurality of analyte monitoring and automatic drug delivery systems can be classified into the same wireless network, so that the physical states and treatment conditions of a plurality of patients can be monitored in real time, and warning can be given out immediately when the physical states of the patients are abnormal. It should be understood that the transmitter 36, specifically the low frequency signal transmitter 36 composed of an oscillation circuit, may have other structures, and this embodiment is not limited in this respect.
In an integrated manner, in the analyte monitoring and automatic drug delivery system provided by this embodiment, in actual operation, the injection device 1 includes a detection component 11, an injection component 13 and a substrate, the injection component 13 is used for injecting a drug, the detection component 11 is disposed on the substrate, the detection component 11 mainly includes a photochemical sensor, the detection component 11 performs sampling detection on the detected analyte, and transmits the detection result to the temporary storage device 2 through an optical signal and a circuit for transient storage; the temporary storage device 2 is connected with the injection device 1 through a circuit, the temporary storage device 2 stores the detection result and then transmits the detection result to the main control device 3, the main control device 3 is connected with the temporary storage device 2 through a circuit, after the main control device 3 receives the detection result, the main control device 3 comprises a processor 31, a controller 32, an input device 37, a prompter 33, a display 34 and a storage 35, the processor 31 comprises a processing unit 311, a comparison unit 312, a calculation unit 313 and a setting unit 314, firstly, the processing unit 311 analyzes and processes the detection result of each detection part 11, and thus a processing value corresponding to the detection result of each detection part 11 is obtained; then, the calculating unit 313 further calculates the detection result of each detection component 11 analyzed and processed by the processing unit 311 to obtain a processing value corresponding to the detection result of each detection component 11; then the comparing unit 312 compares at least one comparison value with a preset threshold value, wherein at least one comparison value is greater than the preset threshold value, and the prompter 33 gives an alarm; the setting unit 314 is then electrically connected to the controller 32, such that various settings of the analyte monitoring device made by the user via the setting unit 314 can be controlled by the control unit for each of the other units; the controller 32 is used for controlling the injection device 1 and the processor 31, the main control device 3 further comprises a prompter 33, if at least one comparison value is compared with a preset threshold value through the comparison unit 312, wherein at least one comparison value is larger than the preset threshold value, the prompter 33 gives an alarm; the main regulation device 3 further comprises: an input device 37 by which a user can input personal information into the automatic drug injection system through the input device 37; the main control device 3 further comprises a display 34, and the display 34 is used for displaying the calculation result of the processor 31; and a storage 35, the storage 35 stores the calculation result of the processor 31; the display 34 and the storage 35 are respectively electrically connected with the controller 32; the regulation and control device also comprises: a transmitter 36, wherein the transmitter 36 is used for transmitting the calculation result of the calculation unit 313 and/or the calculation result stored in the storage 35, if an application software (mobile phone App) adapted to the analyte monitoring and automatic drug delivery system provided by the present invention is installed in the mobile phone of the user, the physical state of the patient can be grasped at any time by pairing with the transmitter 36 (for example, bluetooth pairing, wireless network pairing, etc.), so that the calculation result of the calculation unit 313 and/or the calculation result stored in the storage 35 can be easily obtained on the mobile phone.
Further, it is noted that the preferred embodiment of the present invention is described in the context of a monitoring and drug (insulin) injection system for the treatment of only one disease (diabetes). However, it will be readily apparent to those skilled in the art that the analyte monitoring and automatic drug delivery system provided by the present invention can be used for drug injection for various diseases, for example, for controlling the injection of drugs such as hyperlipidemia and hypertension of patients, which can be arbitrarily selected according to the actual use requirements without any additional creative labor.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.

Claims (10)

1. An analyte monitoring and automatic drug delivery system is characterized by comprising a filling device, a temporary storage device and a main control device,
the injection checking device is detachably connected with the temporary storage device or the main regulation and control device;
the temporary storage device is detachably connected with the main control device;
the injection device includes a substrate and at least two detection parts, at least two injection parts, each of the detection parts for detecting an analysis object in an analyte, each of the injection parts for injecting a medicine, each of the detection parts and each of the injection parts being formed as a needle-shaped member having one end attached to one side surface of the substrate and having a fluid passage formed therein, and the other end of each of the detection parts and each of the injection parts being formed as a tip; the depth of each detection part and each injection part inserted into the interstitial tissue of a patient is between 0.3mm and 5 mm;
the temporary storage device comprises a temporary data storage device and a temporary medicine storage device;
the temporary data storage device is used for temporarily storing the detection result of each detection component; sending the stored detection result to the main control device;
the temporary drug storage device comprises a first drug storage component and a piston type pushing member;
the main control device comprises a second medicine storage part and an injection pump;
the base sheet further comprises a drug dispensing passage through which the first drug storage part or the second drug storage part communicates with each of the injection parts.
2. The analyte monitoring and automatic drug delivery system of claim 1, wherein the priming device is removably connected to the temporary storage device by a first connector;
the injection detecting device is detachably connected with the main regulating device through a second connecting piece;
the temporary storage device and the main control device are detachably connected through a third connecting piece.
3. The analyte monitoring and automatic drug delivery system of claim 2, wherein the master control device further comprises a processor and a controller,
the processor analyzes and processes the detection result of each detection component to obtain a processing numerical value corresponding to the detection result of each detection component; the processor is also used for comparing and calculating the processing value corresponding to each detection component to obtain an instant monitoring result; the processor is further configured to calculate a total injection volume of the drug;
the controller is used for controlling the injection device and the processor, and the controller is electrically connected with the processor.
4. The automatic drug injection device of claim 3, wherein:
the processor calculates the total injection amount of the medicine according to the weight, the waist-hip ratio, the content of triglyceride in blood, the blood glucose monitoring value before meals and the blood glucose change trend in three days of a patient; and is
The processor calculates a total injection volume of the drug according to the following formula:
Figure FDA0001790394150000021
wherein:
L1: a total injected amount (u) of the drug calculated by the processor;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: and a is 0.6.
5. The automatic drug injection device of claim 3, wherein:
the processor calculates the total injection amount of the medicine according to the weight, the waist-hip ratio, the triglyceride content in blood, the pre-meal blood sugar monitoring value, the post-meal blood sugar monitoring value and the blood sugar change trend in three days of the patient; and is
The processor calculates a total injection volume of the drug according to the following formula:
Figure FDA0001790394150000031
wherein:
L2: a total injected amount (u) of the drug calculated by the processor;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: a is 0.6; and
b: mean blood glucose (mmol/L) after a single day of injection of the subject;
b: a trend of postprandial blood glucose change within three days of the injected subject, wherein:
when the postprandial blood glucose change for the injected subjects was overall within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes after three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 10% and within 20% compared with the blood glucose minimum value: a is 1.2;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 20% and within 30% compared with the blood glucose minimum value: a is 1.3;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 30% and within 40% compared with the blood glucose minimum value: a is 1.4;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 40% compared with the blood glucose minimum value: a is 1.5; and is
When the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 10% compared with the blood sugar maximum value: a is 0.9;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 40% compared with the blood sugar maximum value: a is 0.6; and is
Medicine injection amount L before breakfast21＝L2×0.6；
Medicine injection L before supper22＝L2×0.4。
6. The analyte monitoring and automatic drug delivery system of claim 3, wherein each of the detection components includes a working electrode and a reference electrode, the working electrode and the reference electrode being formed of different materials; an electron transfer layer is further arranged on the peripheral surface of each working electrode;
the processor is used for analyzing and processing the electric signals between the working electrode and the reference electrode in each detection part, so as to obtain corresponding processing values corresponding to each detection part.
7. The analyte monitoring and automatic drug delivery system of claim 6, wherein the master control device further comprises:
an input device through which a user may input personal information into the analyte monitoring and automatic injection system,
the processor may also accept user settings for the analyte monitoring and automatic drug delivery system.
The input device and the processor are electrically connected with the controller.
8. The analyte monitoring and automatic drug delivery system according to claim 7, wherein the master control device further comprises a prompt, and the processor is further configured to compare the processing values corresponding to the detection results of the detection components one by one, and compare the comparison values obtained after the one-by-one comparison with the preset monitoring threshold values; and the processor is further configured to compare the total injected amount of the drug to a medication threshold;
if the monitoring comparison value is larger than the monitoring threshold value and/or the total injection amount of the medicine is smaller than the medication threshold value, the prompting unit sends a prompting signal;
the prompter is electrically connected with the controller.
9. The analyte monitoring and automatic drug delivery system of claim 8, wherein the master control device further comprises:
a display for displaying the calculation result of the processor; and
a storage to store the computation results of the processor;
the display and the storage are respectively electrically connected with the controller.
10. The analyte monitoring and automatic drug delivery system of claim 9, wherein the master control device further comprises a transmitter for transmitting the processor's calculations and/or the calculations stored in the memory.
CN201811033862.9A 2018-09-05 2018-09-05 Analyte monitoring and automatic drug delivery system Pending CN110876624A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811033862.9A CN110876624A (en) 2018-09-05 2018-09-05 Analyte monitoring and automatic drug delivery system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811033862.9A CN110876624A (en) 2018-09-05 2018-09-05 Analyte monitoring and automatic drug delivery system

Publications (1)

Publication Number Publication Date
CN110876624A true CN110876624A (en) 2020-03-13

Family

ID=69727643

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811033862.9A Pending CN110876624A (en) 2018-09-05 2018-09-05 Analyte monitoring and automatic drug delivery system

Country Status (1)

Country Link
CN (1) CN110876624A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290910B1 (en) * 1999-03-03 2001-09-18 University Of North Florida Continuously variable volume chamber for flow injection analysis
CN102949178A (en) * 2011-08-16 2013-03-06 伊西康内外科公司 Drug delivery system with procedure stage based delivery adjustment
CN103933632A (en) * 2014-05-12 2014-07-23 李扬 Full-automatic medicine infusion pump
CN106983951A (en) * 2017-05-04 2017-07-28 梁曦 A kind of analyte monitoring and automatic chemical feeding system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290910B1 (en) * 1999-03-03 2001-09-18 University Of North Florida Continuously variable volume chamber for flow injection analysis
CN102949178A (en) * 2011-08-16 2013-03-06 伊西康内外科公司 Drug delivery system with procedure stage based delivery adjustment
CN103933632A (en) * 2014-05-12 2014-07-23 李扬 Full-automatic medicine infusion pump
CN106983951A (en) * 2017-05-04 2017-07-28 梁曦 A kind of analyte monitoring and automatic chemical feeding system

Similar Documents

Publication Publication Date Title
WO2018201931A1 (en) Analyte monitoring and automatic medication delivery system
CN115361981A (en) Redundant interleaved glucose sensor disease management system
CN102711596B (en) Analyte testing method and system
US9504412B2 (en) Method and system to derive glycemic patterns from clustering of glucose data
US20200297997A1 (en) Mechanical Coupling Of An Analyte-Selective Sensor And An Infusion System And Information Conveyance Between The Same
US20100268043A1 (en) Device and Method for Preventing Diabetic Complications
CN101998840A (en) Method and device for non-invasive determination of the concentration of a substance in a body fluid
AU2013315694A1 (en) Method and system to indicate glycemic impacts of insulin infusion pump commands
JP2012020177A (en) Method and system for providing integrated medication infusion/analyte monitoring system
CN105377121A (en) Insertion-site decision-support systems and methods
US20230075014A1 (en) System and method for disease risk assessment and treatment
KR102392948B1 (en) Blood Glucose Index Calculation Method of Non-invasive Type and Non-invasive Blood Glucose Index Measurement System Thereof
KR20150038189A (en) Method and system to manage diabetes using multiple risk indicators for a person with diabetes
US20230389837A1 (en) Analyte sensor for measuring at varying depths within a user
Tagliente et al. Management and treatment of type 1 and 2 diabetes: state of art
CN110876624A (en) Analyte monitoring and automatic drug delivery system
Spanakis et al. Diabetes management: Devices, ICT technologies and future perspectives
CN108982604A (en) The portable monitoring system of analyte in a kind of dynamic METHOD FOR CONTINUOUS DETERMINATION body fluid
CN208921649U (en) A kind of analyte monitoring system
CN110876823A (en) Automatic medicine injection system
CN110879240A (en) Analyte monitoring system
CN207886209U (en) A kind of analyte monitoring device
US20190069822A1 (en) Sensor device for detecting at least one analyte in a body fluid of a user
WO2021096450A1 (en) A tracking device for diabetes patients
CN108784713A (en) A kind of analyte monitoring device

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200313

RJ01 Rejection of invention patent application after publication